Introduction {#s1}
============

Methotrexate (MTX) is the first line treatment for the majority of patients with juvenile idiopathic arthritis (JIA). However, the efficacy of MTX varies greatly among individuals, with about 30 to 70% of JIA patients being effective ([@B35]; [@B14]). Patients who respond to MTX poorly are given biologicals alone or in co-treatment with MTX. Biologics can lead to more efficient disease control, but abuse of biologics can result in high costs and serious adverse reactions. Additionally, it usually takes 3--6 months before a decision is made as to MTX efficacy ([@B30]). Patients receiving "trial-and-error" therapy for such a long time may delay treatment, resulting in irreversible joint damage and even adverse reactions. Therefore, early identification of whether the patient is effective before starting MTX and then selection of appropriate therapy (MTX alone or combined with biologics) are of great significance for preventing disease progression. This means that it is very necessary to establish an efficacy prediction model before the onset of MTX in JIA.

Although MTX has been used to treat JIA for a long time, being able to predict who will respond to MTX is still very limited. To date, only [@B6] reported a predictive model for MTX response to JIA. However, the limitations of this model are as follows: the prediction accuracy was not high (the area under the curve, AUC, was only 72%); model variables contained controversial single nucleotide polymorphisms (SNPs), which required additional and expensive testing, thus limiting its widely available in clinical application. Moreover, this study only employed one traditional logistic regression algorithm, which is not applicable to the modeling of non-independent variables. In addition to this study, other studies on MTX response to JIA were only limited to discovering which indicators would affect the efficacy of MTX. But they did not provide a model for clinical application, so that it could not be easily applied in clinical practice ([@B18]; [@B37]; [@B10]; [@B38]).

Therefore, a simple, efficient and accurate MTX response prediction model is urgently needed to provide references for clinicians before treatment. In recent years, the predictive model developed by machine learning based on electronic medical record (EMR) data has played an excellent role in disease diagnosis, treatment, and prognosis. For example, in our previous work, we used a machine learning technique to acquire pediatric EMR and developed an auxiliary decision-making system for diseases diagnosis, which is comparable to that of human physicians ([@B27]); Machine learning is also used to predict the efficacy and prognosis of diseases in other diseases ([@B31]; [@B4]). Similarly, in rheumatoid diseases, researchers used machine learning to establish disease diagnosis classifier, mortality prediction model and MTX related hepatotoxicity automatic recognizer basing on EMR data ([@B28]; [@B29]; [@B26]). These results provide practical tools for the management of patients. However, currently, there are no reports about the prediction model of MTX response in JIA using machine learning only basing on EMRs.

The purpose of this study is to develop simple, efficient and accurate models using machine learning for early predicting the efficacy of MTX in JIA based on integrating temporal features before and after starting MTX within three months.

Methods {#s2}
=======

Study Design and Population {#s2_1}
---------------------------

We retrospectively collected the EMR data of children with JIA who visited Guangzhou Women and Children's Medical Center from January 2008 to October 2018. Inclusion criteria were: (1) patients were new-onset and met the International League of Associations for Rheumatology criteria for JIA ([@B32]; [@B30]). (2) The onset age was 1--16 years old. (3) Patients received monotherapy with MTX for at least 3 months. (4) Co-treatment with non-steroidal anti-inflammatory drugs or corticosteroids were allowed. Exclusion criteria were: (1) combined therapy with other interfering drugs (e.g. biologic agents, sulfasalazine, etc.) within 3 months. (2) MTX therapy did not reach 3 months. (3) Serious missing of medical records. A total of 674 JIA children using MTX were screened out, but 362 patients were eventually included for modeling and validating. Furthermore, we continued to collect 13 JIA patients from November 2018 to January 2019 for external verification.

The study was performed according to the Helsinki declaration. Ethical approval was obtained from the ethics committee of this center (no. 2016021645). This study was a part of a large clinical trial (NCT81603203). All data were anonymous and no identifiable personal data of patients were available for the analysis. No additional informed consent was required.

Assessment of MTX Clinical Response {#s2_2}
-----------------------------------

Weekly MTX was given to all patients by either oral or subcutaneous route at 10--15 mg/m^2^. Baseline disease activity was calculated before MTX treatment. Early response to MTX was evaluated at 3 months after using MTX. Since it is a retrospective study, it is difficult to collect subjective features such as patient/parent and physician's global assessment of disease. Therefore, JADAS or ACRpedi (see [**Table 1**](#T1){ref-type="table"} for the full name) scoring tools could not be applied to evaluate the response ([@B16]; [@B11]). DAS44/ESR-3, a simplified standard related to the European League of Associations for Rheumatology criteria, was the most suitable choice for this retrospective study ([@B33]; [@B11]). The simplified formula of the disease activity is as follows: $y = 0.53938\sqrt{RAI} + 0.06465*SJC44 + 0.33\ln\left( {ESR} \right) + 0.224$ (RAI, Ritchie articular index; SJC, Swollen joint count; ESR, erythrocyte sedimentation rate). The response was defined as a significant change of DAS44 scores from baseline to 3 months after starting MTX. Good response was defined as a significant decrease in DAS44 (\>0.6), while a decrease of ≤0.6 was non-response.

###### 

The full name and abbreviation name of variables.

  Full name of variables               Abbreviation name   Full name of variables                                  Abbreviation name
  ------------------------------------ ------------------- ------------------------------------------------------- -------------------
  Age of methotrexate start            Age of MTX start    Hemoglobin                                              HGB
  Age onset                            Age onset           Indirect bilirubin                                      IBIL
  Albumin                              ALB                 Immune globulin A                                       IgA
  Alanine transaminase                 ALT                 Immune globulin E                                       IgE
  Anti-cyclic citrullinated peptide    Anti-CCP            Immune globulin G                                       IgG
  Active partial thrombin time         APTT                Immune globulin M                                       IgM
  Aspartate aminotransferase           AST                 JIA subtype                                             JIA subtype
  Complement 3                         C3                  Lymphocyte                                              LYM
  Complement 4                         C4                  Neutrophil                                              NEUT
  CD16+CD56+                           CD16+CD56+          Platelet                                                PLT
  CD19+                                CD19+               Prothrombin time                                        PT
  CD3+Abs                              CD3+Abs             Red blood cell                                          RBC
  CD3+CD4+                             CD3+CD4+            Rheumatoid factor-IgG                                   RF-IgG
  CD3+CD8+                             CD3+CD8+            Serum creatinine                                        SCr
  C-reactive protein                   CRP                 Swollen joint count                                     SJC
  Direct bilirubin                     DBIL                Total bilirubin                                         TBIL
  The first dose of MTX on the start   Dose0               Helper T cells/Suppressor T cells                       Th/Ts
  Erythrocyte sedimentation rate       ESR                 Time interval                                           Time interval
  Ferritin                             FER                 Tender joint count                                      TJC
  Fibrinogen                           FIB                 Thrombin time                                           TT
  Gender                               Gender              Urea                                                    Urea
  Blood glucose                        GLU                 White blood cell                                        WBC
  Hematocrit                           HCT                 Weight                                                  Weight
  Ritchie articular index              RAI                 C-reactive protein near 3 months after administration   CRP/3m

CD, Cluster of differentiation cell; CD3+Abs, the absolute value of T cell with Cluster of differentiation 3; CD3+CD4+, the ratio of CD4+ divided by CD3+.

Variables with the suffix "/3m" are those collected within 3 months after administration of MTX. For example, CRP/3m refers to the CRP variable collected within 3 months after administration.

Clinical Variables {#s2_3}
------------------

All data were collected from EMRs before administration of MTX (baseline) and within 3 months after administration (nearly 3 months). We collected a lot of variables, including: joint conditions \[tender joint count (TJC), SJC, RAI, and JIA subtypes (oligoarticular, polyarticular, and other subtypes), joint imaging, etc.\], the acute phase of inflammatory products \[C-reactive protein (CRP), ESR\], demographic data (age, gender, etc.), immune-related indicators \[rheumatoid factor (RF), rheumatoid factor IgG (RF-IgG), antinuclear antibodies, anti-cyclic citrullinated peptide antibody, etc.\], kidney function, liver function \[total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin (IBIL), etc.\], blood coagulation function \[active partial thrombin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), etc.\], blood routine testing, relevant lymphocytes (CD3+abs, CD3+CD4+, CD3+CD8+, etc.) and other data. See [**Table 1**](#T1){ref-type="table"} for a list of all variables. Because some variables were seriously missing, they were not be used for modeling. All variables used for modeling are shown in [**Figure 1**](#f1){ref-type="fig"}.

![The variables used for modeling and their importance ranking (in order of median importance). The left part of the figure shows the variables used in the pre-administration variables model. The right part of the figure shows a mixture of variables before and after administration (variables collected within 3 months after administration with MTX). The shorter the transverse column (i.e. the smaller the value), the greater importance of the median ranking of the variable (see the top and left part).](fphar-10-01155-g001){#f1}

Machine Learning {#s2_4}
----------------

We collected two different sets of variables. Thus, two groups of models were established based on variables before the onset of MTX and mix-variables within 3 months after starting MTX respectively, for finding the best model. In the first group of models, referred to as pre-administration variables models (MTX-A), we included 46 variables (see the left part of [**Figure 1**](#f1){ref-type="fig"}). In the second group of models, referred to as mix-variables models (MTX-B), we extended MTX-A by adding 32 new variables (see the right part of [**Figure 1**](#f1){ref-type="fig"}). The main process can be divided into three steps: (1) data processing, (2) feature selection, (3) model generation and validation. Five-fold stratified cross-validation was used for assessing the performance and general error estimation of feature selection and model generation. [**Figure 2**](#f2){ref-type="fig"} shows the flowchart of this work. Machine learning techniques were implemented in Python 3 (Python 3.6.5) using the package Scikit-learn (Scikit-learn 0.19.1).

![The flowchart of model developing and validation. ET, extremely randomized trees; GBDT, gradient boosting decision tree; RF, random forest; XGBoost, extreme gradient boosting; SVM, support vector machine; LR, logistic regression.](fphar-10-01155-g002){#f2}

Data Preprocessing {#s2_5}
------------------

Some variables have been removed with \>30% missing rates. In order to get a higher quality of the dataset, the missing values were filled with mean values of a group stratified by MTX response. For example, we used mean values of good response and non-response group to respectively fill the data of CRP in different outcome groups.

Feature Selection {#s2_6}
-----------------

Appropriate feature subsets were selected using ensemble models, including extremely randomized trees (ET), gradient boosting decision tree (GBDT), random forest (RF) and extreme gradient boosting (XGBoost). Firstly, data transformation was carried out on continuous variables to form four kinds of data: min-max normalization, z-score normalization, L2 normalization and original. Secondly, the above four algorithms were used to analyze the four forms of data and build 16 models using five-fold stratified cross-validation, so as to obtain the median importance ranking of variables in all models which is as the final features importance ranking. Finally, the next aim is to determine the feature set with the least variables but the highest predictive accuracy. The XGBoost algorithm was used to find the minimum-size list of features by forwarding feature selection, as follows: (1) beginning with the head of the ranked list of variables (the most important variable), XGBoost algorithm iteratively generates a new model by adding one variable at a time, and calculates its classification accuracy. (2) The list with the minimum size and optimum accuracy is therefore selected.

Model Generation and Validation {#s2_7}
-------------------------------

A cohort of 362 patients was randomly split into the training set and test set according to the ratio of 80:20. XGBoost, RF, support vector machine (SVM) and logistic regression (LR) algorithms were applied to develop classifiers respectively in our study. The classifiers were trained on the training set (n = 289), using the training set feature values (the minimum-size list of features) as input. Thus, each set of variables had 4 types of classifiers. Five-fold stratified cross-validation was used for internal validation. After training, classifiers were asked to predict the response of the test set (n = 73). For each set of variables, the four classifiers were compared with each other in terms of accuracy, and then the best classifier was selected as the final predictor. We further performed an external validation of the above classifiers with the subsequent collection of 13 patients.

Results {#s3}
=======

Patient Characteristics {#s3_1}
-----------------------

A total cohort of 362 patients with JIA was included in developing models, and 13 patients were subsequently collected to external validate the best model. [**Table 2**](#T2){ref-type="table"} describes the baseline characteristics of our study population. According to DAS44/ESR-3 simplified standard, 213 patients were rated as good response and 149 patients as non-response.

###### 

Baseline patient characteristics.

  Characteristics                                 Data (n = 362)
  ----------------------------------------------- ----------------
  Gender, n (male/female)                         211/151
  Age of MTX start, years, (mean ± SD)            6.7 ± 3.4
  Age of disease onset, years, (mean ± SD)        6.3 ± 3.4
  Time interval\*, months, (mean ± SD)            5.6 ± 2.7
  Polyarticular JIA, n                            101
  Oligoarticular JIA, n                           186
  Other types of JIA, n                           75
  Tender joint count, median (range)              3(0--36)
  Swollen joint count, median (range)             4(0--36)
  ESR, mm/h, (mean ± SD)                          36.22 ± 33.34
  CRP, mg/L, (mean ± SD)                          24.81 ± 33.32
  RF-IgG, U/ml, (mean ± SD)                       23.68 ± 52.55
  MTX dose at start, mg/m^2^/wk, median (range)   5.0(0.5--18.0)

\*Time interval, the time from disease onset to initiation of MTX treatment.

Feature Selection {#s3_2}
-----------------

Median importance ranking of all variables before using MTX and mix-variables before and after administering with MTX were shown in [**Figure 1**](#f1){ref-type="fig"} (left part and right part). The XGBoost algorithm was applied for selecting the minimum size and optimum accuracy features subset, and the results of this process were shown in [**Figure 3**](#f3){ref-type="fig"}. We examined the predictive performance of the most prominent feature and identified the point at which there was no considerable gain in accuracy, sensitivity, and AUC, when adding the feature of the next highest ranking one to the model. The optimum values were obtained when these three measurements defined the most discriminative features. In the MTX-A predictors, the three measurements reached the optimum when 10 feature subsets were selected (see [**Figure 3A**](#f3){ref-type="fig"}). The 10 selected significant variables are listed above the dotted red line in the left part of [**Figure 1**](#f1){ref-type="fig"}. In the MTX-B predictors, the three measurements achieve maximum performance when 6 feature subsets were screened out (see [**Figure 3B**](#f3){ref-type="fig"}). Variables above the dotted red line in the right part of [**Figure 1**](#f1){ref-type="fig"} are these 6 features. The degree of contribution of all the above selected variables to response and the formulas behind modeling were described in detail in the [**Supplementary**](#SM1){ref-type="supplementary-material"}.

![The forward feature selection results for the model of pre-administration variables (the **A** part of figure 3) and the model of mix-variables before and after administration (the **B** part of figure 3). We examined the predictive performance of the most prominent feature and identified the point at which there was no considerable gain in accuracy, sensitivity, and area under the curve (AUC), when adding the feature of the next highest ranking one to the model. The optimum values were obtained when these three measurements defined the most discriminative features.](fphar-10-01155-g003){#f3}

Model Performance and Comparison {#s3_3}
--------------------------------

[**Table 3**](#T3){ref-type="table"} shows the classification accuracy results of the models which were evaluated using the test set. Of the MTX-A and MTX-B predictors, both the XGBoost models showed the best predictive performances. Therefore, the XGBoost models were selected as the final predictors. The performance of MTX-A XGBoost predictor was as follows: sensitivity 90.70% (95%CI: 82.0--99.4%), specificity 93.33% (95%CI: 84.4--100%), accuracy 91.78% (95%CI: 85.5--98.1%) and AUC 0.97. However, the MTX-B XGBoost predictor have a better performance, which achieves sensitivity 95.35% (95%CI: 89.0--100%), specificity 93.33% (95%CI: 84.4--100%), accuracy 94.35% (95%CI: 89.3--99.7%) and AUC 0.99. [**Figure 4**](#f4){ref-type="fig"} shows the mixed matrix results of each model in the MTX-A and MTX-B predictors of the test set.

###### 

The classification performance results of the models.

  ----------------------------------------------------------------------------------------------
  Data set   Model     Sensitivity (%)   Specificity (%)   Accuracy (%)   PPV\    NPV\    AUC
                                                                          (%)     (%)     
  ---------- --------- ----------------- ----------------- -------------- ------- ------- ------
  MTX-A      XGBoost   90.70             93.33             91.78          95.12   87.50   0.97

  RF         90.70     80.00             86.30             86.67          85.71   0.95    

  SVM        79.07     83.33             80.82             87.18          73.53   0.87    

  LR         65.12     73.33             68.49             77.78          59.46   0.80    

  MTX-B      XGBoost   95.35             93.33             94.52          95.35   93.33   0.99

  RF         95.35     93.33             94.52             95.35          93.33   0.98    

  SVM        88.37     80.00             84.93             86.36          82.76   0.81    

  LR         88.37     76.67             83.56             84.44          82.14   0.83    
  ----------------------------------------------------------------------------------------------

MTX-A, pre-administration variables prediction models; MTX-B, mix-variables models with features collected before and after administered with MTX within 3 months; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve; XGBoost, extreme gradient boosting; RF, random forest; SVM, support vector machine; LR, logistic regression.

![The mixed matrix results of each model in the MTX-A and MTX-B predictors of the test set. For example, when the true lables were NR(non-response) and predicted lables were NR, it indicated that the number of NR was correctly predicted. However, when true lables were NR, and predicted labels were GR (good response), it indicated the number of NR incorrectly predicted to GR. As can be seen from the figure, the predicted values of model A (XGBoost model) and model E (XGBoost model) are the closest to the real values, indicating the best prediction performance. The numbers in the pink grids represent the number of cases that were accurately predicted.](fphar-10-01155-g004){#f4}

External Verification and Clinical Application {#s3_4}
----------------------------------------------

Data of 13 patients newly collected were applied to externally validate the two XGBoost predictors. The performances of MTX-A XGBoost predictor were sensitivity 100.0%, specificity 86.1% and accuracy 90.0%, respectively. But the MTX-B XGBoost predictor got better performance results, with 100% sensitivity, specificity, and accuracy. Furthermore, we applied these predictors to two randomly selected patients to predict their outcomes. We input their clinical variables into the two predictors. Both models produced correct predictive outcomes (see [**Table 4**](#T4){ref-type="table"}).

###### 

The application of XGBoost predictors for clinical patients to predict their response.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  MTX-A\      Patient name     Input variables   Output                                                                                          
  Predictor                                                                                                                                      
  ----------- ---------------- ----------------- ----------------- ---------- ---------- ------- ------- ---------- ---------- ------ ---------- ----------
              AAA              35.30             2.77              34.20      2,454.46   12.00   10.90   1          21.50      1.30   4.80       Non-\
                                                                                                                                                 response

  BBB         150.00           4.71              26.22             3,309.00   14.40      10.90   2       5.90       2.60       2.70   Good\      
                                                                                                                                      response   

  MTX-B\      Patient name     Input variables   Output                                                                                          
  Predictor                                                                                                                                      

  CRP/3m\     CD3+CD4+/3m(%)   CD3+CD8+/3m\      RF-IgG/3m(U/ml)   TBIL/3m\   FIB(g/L)                                                           
  (mg/L)                       (%)                                 (umol/L)                                                                      

              AAA              49.60             38.00             50.00      11.70      6.17    2.77               Non-\                        
                                                                                                                    response                     

  BBB         32.30            34.44             26.77             3.90       7.60       4.71            Good\                                   
                                                                                                         response                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

In this table, variables were from clinical determination. The patient named AAA was responded to MTX in clinic practice, but the patient named BBB was not responded to MTX. We input their clinical variables into the two predictors. Both models produced correct predictive outcomes. Output means the prediction results of the MTX response.

Discussion {#s4}
==========

We developed and validated two prediction models for MTX response in a large JIA cohort according to EMR data using machine learning. Models developed by XGBoost showed the best performance. CRP, CD3+Abs, RF-IgG, TJC, DBIL, IBIL, APTT, PT, TT, and FIB were variables screened out by the pre-administration variables model; and the mix-variables model filtered out features as follows: CRP/3m, CD3+CD4+/3m, CD3+CD8+/3m, RF-IgG/3m, TBIL/3m, and FIB, which were collected before and after administering MTX. The pre-administration variables model could accurately identify ninety-seven percent of patients whether responded to MTX (AUC 97%); 99% of patients were distinguished by the mix-variables model (AUC 99%).

To our knowledge, this is the first article to establish an accurate and easy-to-use predictive model for the efficacy of MTX in JIA based solely on EMRs using machine learning. [@B6] reported the first and so far the only one efficacy prediction model, which including variables of SNPs and ESR. The identified accuracy, sensitivity, specificity, positive predictive value, negative predictive value were 72, 78, 49, 83, and 41%, respectively. These results were all lower than ours. SNPs are important in precision medicine. However, a GWAS study found no direct correlation between SNPs related to the pathways of MTX and the efficacy in 759 JIA patients ([@B10]). This suggests that SNPs may not necessary in revealing the outcome of JIA ([@B1]; [@B34]). Moreover, the expression and activity of enzymes in children may be affected by growth, and the genotype may not directly reflect the phenotype ([@B40]; [@B34]). In addition, genotype detection increases the cost and time, which is not as convenient, efficient and cheap as conventional detection. These suggest that clinical phenotypic variables may be more important in influencing outcomes ([@B34]). Our results verified the above view.

Of course, the low prediction accuracy of Bulatovic's study may be because of using only the traditional logistic regression, which may not be the optimal method. Machine learning is hot in recent years, which has gained remarkable achievements in biomedicine ([@B2]; [@B29]; [@B31]; [@B4]; [@B27]). Specifically, machine-learning approaches may offer advantages over conventional techniques. The advantages of machine learning over traditional modeling methods are as follows: (1) machine learning can deal with more complex, high-dimensional and interactive variables, but the latter has limited ability to fix those problems. (2) Traditional modeling has poor generalization, though the former can model with strong generalization and better accuracy ([@B23]; [@B25]). Therefore, several advanced machine learning methods including SVM, RF, and XGBoost as well as LR were applied to model and compare the results in our study. Of our results, the performances of XGBoost models were the best, and the results of LR models were mostly poor. Further, the performances of those four modeling methods were all better than those of Bulatovic's study. These results also confirmed that XGBoost could effectively avoid overfitting and improve prediction performance. LR, as a kind of traditional analysis, may appear low-fitting ([@B24]). Therefore, when dealing with similar classification problems, it may be more appropriate to select advanced algorithms.

In addition to the above Bulatovic's study, other literature also explored which variables were associated with the efficacy of MTX ([@B37]; [@B10]; [@B38]). But they did not establish a model, which could not be applied easily in clinical. For instance, some studies showed SNPs were associated with MTX efficacy ([@B18]; [@B12]; [@B38]) clinical variables like TJC, ESR, CRP, etc. were also correlated with MTX response ([@B1]; [@B37]; [@B10]; [@B15]). Variables considered in our study (n = 78) were more than and mostly different from those of the reported studies ([@B1]; [@B37]; [@B10]; [@B15]). TJC, CRP and RF-IgG screened out by our study were reported to associate with disease activity, prognosis, efficacy of rheumatoid arthritis or JIA ([@B39]; [@B7]; [@B21]). CD3+, CD4+, and CD8+ are the most important T lymphocytes, which are widely distributed in the joint synovial membrane and fluid and play an important role in the pathogenesis and classification of JIA ([@B13]; [@B19]; [@B36]). One mechanism of MTX action is to regulate or inhibit T cell immunity to achieve the therapeutic effect ([@B22]). In this study, these cells were contributed to MTX outcome, which is consistent with the MTX effect mechanism and similar to some reports ([@B20]; [@B5]). Liver function variables (TBIL, DBIL, and IBIL) were also screened out. It is well-known that MTX is metabolized by the liver, so its pharmacokinetics will be affected by liver function, which will then affect pharmacodynamics. Coagulation markers (APTT, PT, TT, and FIB) also contributed to MTX efficacy in our study. We know ESR is an important variable in calculating disease activity and MTX efficacy. While ESR depends mainly on plasma FIB ([@B3]). Additionally, FIB affects the adhesion, spread, proliferation of endothelial cells, and the repair of joint synovial tissue. So FIB may have an indirect contribution to MTX treatment ([@B8]; [@B9]; [@B17]). As for the degree of contribution of all the above selected variables to the outcome (efficacy), we described details in the [**Supplementary**](#SM1){ref-type="supplementary-material"}. It can be seen from the [**Supplementary**](#SM1){ref-type="supplementary-material"} that CRP was the most significant variable for the pre-administration model, while for the mix-variables model, RF-IgG/3m was the most important.

Additionally, from our results, the mix-variables model was better than the pre-administration variables model. This indicated that temporal features after administration but before evaluating efficacy also had an important influence on the treatment outcome. Just as variables before and during pregnancy can both have an impact on pregnancy outcome. This suggests that in addition to considering the influence of pre-administration variables, the efficacy should be evaluated in combination with post-administration features. The limits of this study were the relatively small sample size, insufficient representativeness of externally verified samples and retrospective research. The next step is to conduct prospective studies to model and validate.

Conclusions {#s5}
===========

In summary, for the first time, based on EMR we used advanced machine learning to establish two early predictive models for the MTX efficacy in JIA, including pre-administration variables model and mix-variables model. The latter model performed better. The variables screened by the models were closely related to the pathogenesis of diseases, pharmacokinetics and pharmacodynamics of MTX, and could be fully explained. Interestingly, the coagulation indicators filtered out by our models may indicate the new pathogenesis of JIA and the unelucidated mechanism of MTX. This model is simple, efficient and accurate, and can be easily generalized by clinicians and pharmacists to make early treatment decisions to patients of different ethnic groups.
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